Pharmacophore modelling, molecular docking and virtual screening for EGFR (HER 1) tyrosine kinase inhibitors

References

• Jordan , JD , Landau , EM and Iyengar , R . 2000 . Signaling networks: The origins of cellular multitasking . Cell , 103 : 193 – 200 .
   PubMed Web of Science ®Google Scholar
• Ferguson , KM , Berger , MB , Mendrola , JM , Cho , HS , Leahy , DJ and Lemmon , MA . 2003 . EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization . Mol. Cell , 11 : 507 – 517 .
   PubMed Web of Science ®Google Scholar
• Olayioye , MA , Beuvink , I , Horsch , K , Daly , JM and Hynes , NE . 1999 . ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases . J. Biol. Chem. , 274 : 17209 – 17218 .
   PubMedGoogle Scholar
• Guy , CT , Cardiff , RD and Muller , WJ . 1996 . Activated neu induces rapid tumor progression . J. Biol. Chem. , 271 : 7673 – 7678 .
   PubMed Web of Science ®Google Scholar
• Olayioye , MA , Neve , RM , Lane , HA and Hynes , NE . 2000 . The ErbB signaling network: Receptor heterodimerization in development and cancer . EMBO J. , 19 : 3159 – 3167 .
   PubMed Web of Science ®Google Scholar
• Moriki , T , Maruyama , H and Maruyama , IN . 2000 . Activation of preformed EGF receptor dimers by ligand-induced rotation of the transmembrane domain . J. Mol. Biol. , 311 : 1011 – 1026 .
   Web of Science ®Google Scholar
• Yu , X , Sharma , KD , Takahashi , T , Iwamoto , R and Mekada , E . 2002 . Ligand-independent dimer formation of epidermal growth factor receptor (EGFR) is a step separable from ligand-induced EGFR signaling . Mol. Biol. Cell , 13 : 2547 – 2557 .
   PubMed Web of Science ®Google Scholar
• Sorokin , A . 1995 . Activation of the EGF receptor by insertional mutations in its juxtamembrane regions . Oncogene , 11 : 1531 – 1540 .
   PubMed Web of Science ®Google Scholar
• Levitzki , A and Gazit , A . 1995 . Tyrosine kinase inhibition: An approach to drug development . Science , 267 : 1782 – 1788 .
   PubMed Web of Science ®Google Scholar
• Fry , DW . 1994 . Protein tyrosine kinases as therapeutic targets in cancer chemotherapy and recent advances in the development of new inhibitors . Exp. Opin. Invest. Drugs , 3 : 577 – 595 .
   Google Scholar
• Traxler , P . 1997 . Protein tyrosine kinase inhibitors in cancer treatment . Exp. Opin. Ther. Patents , 7 : 571 – 588 .
   Web of Science ®Google Scholar
• Bonomi , P . 2003 . Erlotinib: A new therapeutic approach for non-small cell lung cancer . Exp. Rev. Anticancer Ther. , 3 : 367 – 380 .
   PubMedGoogle Scholar
• Baker , J , Gibson , KH , Grudy , W , Godfrey , AA , Barlow , JJ , Healy , MP , Woodburn , JR , Ashton , SE , Curry , BJ , Scarlett , L , Henthorn , L and Richards , L . 2001 . Studies leading to the identification of ZD1839 (iressa™): An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer . Bioorg. Med. Chem. Lett. , 11 : 1911 – 1914 .
   PubMed Web of Science ®Google Scholar
• Rusnak , DW , Lackey , K , Wood , ER , Alligood , KJ , Rhodes , N , Knight , WB and Gilmer , TM . 2001 . The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo . Mol. Cancer Ther. , 1 : 85 – 94 .
   PubMed Web of Science ®Google Scholar
• Yoshimuraa , N , Kudoha , S , Kimuraa , T , Mitsuokaa , S , Matsuuraa , K , Hirataa , K , Matsuib , K , Negoroc , S , Nakagawad , K and Fukuokad , M . 2006 . EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib . Lung Cancer , 51 : 363 – 368 .
   PubMed Web of Science ®Google Scholar
• Wissner , A , Overbeek , E , Reich , MF , Floyd , MB , Johnson , BD , Mamuya , N , Rosfjord , EC , Discafani , C , Davis , R , Shi , X , Rabindran , SK , Gruber , BC , Ye , F , Hallett , WA , Nilakantan , R , Shen , R , Wang , YF , Greenberger , LM and Tsou , HR . 2003 . Synthesis and structure–activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2) . J. Med. Chem. , 46 : 49 – 63 .
   PubMed Web of Science ®Google Scholar
• Ward , WH , Cook , PN , Slater , AM , Davies , DH , Holdgate , GA and Green , LR . 1994 . Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor . Biochem. Pharmacol. , 48 : 659 – 666 .
   PubMed Web of Science ®Google Scholar
• Fry , DW , Kraker , AJ , McMichael , A , Ambroso , LA , Nelson , JM , Leopold , WR , Connors , RW and Bridges , AJ . 1994 . A specific inhibitor of the epidermal growth factor receptor tyrosine kinase . Science , 265 : 1093 – 1095 .
   PubMed Web of Science ®Google Scholar
• Rewcastle , GW , Denny , WA , Bridges , AJ , Zhou , H , Cody , DR , McMichael , A and Fry , DW . 1995 . Tyrosine kinase inhibitors. 5. Synthesis and structure–activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5′-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor . J. Med. Chem. , 38 : 3482 – 3487 .
   PubMed Web of Science ®Google Scholar
• Rewcastle , GW , Palmer , BD , Bridges , AJ , Showalter , HD , Sun , L , Nelson , JM , McMichael , A , Kraker , AJ , Fry , DW and Denny , WA . 1996 . Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor . J. Med. Chem. , 39 : 918 – 928 .
   PubMed Web of Science ®Google Scholar
• Thompson , AM , Bridges , AJ , Fry , DW , Kraker , AJ and Denny , WA . 1995 . Tyrosine kinase inhibitors:7-Amino-4-(phenylamino)- and 7-amino-4-[(phenylmethyl)-amino]pyrido[4,3-d]pyrimidines: A new class of inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor . J. Med. Chem. , 38 : 3780 – 3788 .
   PubMed Web of Science ®Google Scholar
• Traxler , P , Furet , P , Mett , H , Buchdunger , E , Meyer , T and Lydon , N . 1996 . 4-(Phenylamino) pyrrolopyrim-idines: Potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase . J. Med. Chem. , 39 : 2285 – 2292 .
   PubMed Web of Science ®Google Scholar
• Rewcastle , GW , Bridges , AJ , Fry , DW , Rubin , JR and Denny , WA . 1997 . Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptor . J. Med. Chem. , 40 : 1820 – 1826 .
   PubMed Web of Science ®Google Scholar
• Traxler , P , Bold , G , Frei , J , Lang , M , Lydon , N , Mett , H , Buchdunger , E , Meyer , T , Mueller , M and Furet , P . 1997 . Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines . J. Med. Chem. , 40 : 3601 – 3616 .
   PubMed Web of Science ®Google Scholar
• Traxler , P , Green , J , Mett , H , Se’quin , U and Furet , P . 1999 . Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: Isoflavones and 3-phenyl-4(1h)-quinolones . J. Med. Chem. , 42 : 1018 – 1026 .
   PubMed Web of Science ®Google Scholar
• Palmer , BD , Trumpp-Kallmeyer , S , Fry , DW , Nelson , JM , Showalter , HD and Denny , WA . 1997 . Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: Synthesis, biological evaluation, and modeling of the mode of binding . J. Med. Chem. , 40 : 1519 – 1529 .
   PubMed Web of Science ®Google Scholar
• Trumpp-Kallmeyer , S , Rubin , JR , Humblet , C , Hamby , JM and Hollis Showalter , HD . 1998 . Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors . J. Med. Chem. , 41 : 1752 – 1763 .
   PubMed Web of Science ®Google Scholar
• Hollis Showalter , HD , Bridges , AJ , Zhou , H , Sercel , AD , McMichael , A and Fry , DW . 1999 . Tyrosine kinase inhibitors. 16. 6,5,6-tricyclic benzothieno[3,2-d]pyrimidines and pyrimido[5,4-b]- and -[4,5-b]indoles as potent inhibitors of the epidermal growth factor receptor tyrosine kinase . J. Med. Chem. , 42 : 5464 – 5474 .
   PubMed Web of Science ®Google Scholar
• Zhu , LL , Hou , TJ , Chen , LR and Xu , XJ . 2001 . 3D QSAR analyses of novel tyrosine kinase inhibitors based on pharmacophore alignment . J. Chem. Inf. Comput. Sci. , 41 : 1032 – 1040 .
   PubMedGoogle Scholar
• Gundla , R , Kazemi , R , Sanam , R , Muttineni , R , Sarma , AJ , Dayam , R and Neamati , N . 2008 . Discovery of novel small-molecule inhibitors of human epidermal growth factor receptor-2: Combined ligand and target-based approach . J. Med. Chem. , 51 : 3367 – 3377 .
   PubMed Web of Science ®Google Scholar
• Motta , CL , Sartini , S , Tuccinardi , T , Nerini , E , Da Settimo , F and Martinelli , A . 2009 . Computational studies of epidermal growth factor receptor: Docking reliability, three-dimensional quantitative structure–activity relationship analysis, and virtual screening studies . J. Med. Chem. , 52 : 964 – 975 .
   PubMed Web of Science ®Google Scholar
• Pasha , FA , Muddassar , M , Srivastava , AK and Cho , SJ . 2010 . In silico QSAR studies of anilinoquinolines as EGFR inhibitors . J. Mol. Model. , 16 : 263 – 277 .
   PubMed Web of Science ®Google Scholar
• Assefa , H , Kamath , S and Buolamwini , JK . 2003 . 3D-QSAR and docking studies on 4-anilinoquinazoline and 4-anilinoquinoline epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors . J. Comp. Aided Mol. Des. , 17 : 475 – 493 .
   PubMed Web of Science ®Google Scholar
• Pednekar , DV , Kelkar , MA , Pimple , SR and Akamanchi , KG . 2004 . 3D QSAR studies of inhibitors of epidermal growth factor receptor [EGFR] using CoMFA and GFA methodologies . Med. Chem. Res. , 13 : 605 – 618 .
   Web of Science ®Google Scholar
• Lin , R , Johnson , SG , Connolly , PJ , Wetter , SK , Binnun , E , Hughes , TV , Murray , WV , Pandey , NB , Moreno-Mazza , SJ , Adams , M and Fuentes-Pesquera , AR . 2009 . Synthesis and evaluation of 2,7-diamino-thiazolo[4,5-d] pyrimidine analogues as anti-tumor epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors . Bioorg. Med. Chem. Lett. , 19 : 2333 – 2337 .
   PubMed Web of Science ®Google Scholar
• Van Brocklin , HF , Lim , JK , Coffing , SL , Hom , DL , Negash , K , Ono , MY , Gilmore , JL , Bryant , I and Riese , DJ II . 2005 . Anilinodialkoxyquinazolines: Screening epidermal growth factor receptor tyrosine kinase inhibitors for potential tumor imaging probes . J. Med. Chem. , 48 : 7445 – 7456 .
   PubMed Web of Science ®Google Scholar
• Waterson , AG , Petrov , KG , Hornberger , KR , Hubbard , RD , Sammond , DM , Smith , SC , Dickson , HD , Caferro , TR , Hinkle , KW , Stevens , KL , Dickerson , SH , Rusnak , DW , Spehar , GM , Wood , ER , Griffin , RJ and Uehling , DE . 2009 . Synthesis and evaluation of aniline headgroups for alkynyl thienopyrimidine dual EGFR/ErbB-2 kinase inhibitors . Bioorg. Med. Chem. Lett. , 19 : 1332 – 1336 .
   PubMed Web of Science ®Google Scholar
• Kim , SG , Yoon , CJ , Kim , SH , Cho , YJ and Kang , DI . 2000 . Building a common feature hypothesis for thymidylate synthase inhibition . Bioorg. Med. Chem. , 8 : 11 – 17 .
   PubMed Web of Science ®Google Scholar
• H. Li, J. Sutter, and R. Hoffmann, HypoGen: An Automated System for Generating 3D Predictive Pharmacophore Models. In Pharmacophore Perception, Development and Use in Drug Design, International University Line, La Jolla, CA, 2000
   Google Scholar
• Discovery Studio 2.0; Accelrys: 9685 Scranton Road, San Diego, CA 92121, USA
   Google Scholar
• Fischer , R . 1966 . The Principle of Experimentation, Illustrated by a Psycho-physical Experiment. In the Design of Experiments , New York : Hafner Publishing Co. .
   Google Scholar
• Rheault , TR , Caferro , TR , Dickerson , SH , Donaldson , KH , Gaul , MD , Goetz , AS , Mullin , RJ , McDonald , OB , Petrov , KG , Rusnak , DW , Shewchuk , LM , Spehar , GM , Truesdale , AT , Vanderwall , DE , Wood , ER and Uehling , DE . 2009 . Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors . Bioorg. Med. Chem. Lett. , 19 : 817 – 820 .
   PubMed Web of Science ®Google Scholar
• Pannala , M , Kher , S , Wilson , N , Gaudette , J , Sircar , I , Zhang , S , Bakhirev , A , Yang , G , Yuen , P , Gorcsan , F , Sakurai , N , Barbosab , M and Cheng , J . 2007 . Synthesis and structure–activity relationship of 4-(2-aryl-cyclopropylamino)-quinoline-3-carbonitriles as EGFR tyrosine kinase inhibitors . Bioorg. Med. Chem. Lett. , 17 : 5978 – 5982 .
   PubMed Web of Science ®Google Scholar
• Moyer , JD , Barbacci , EG , Iwata , KK , Arnold , L , Boman , B , Cunningham , A , DiOrio , C , Doty , J , Morin , MJ , Moyer , MP , Neveu , M , Pollack , VA , Pustilnik , LR , Reynolds , MM , Sloan , D , Theleman , A and Miller , P . 1997 . Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase . Cancer Res. , 57 : 4838 – 4848 .
   PubMed Web of Science ®Google Scholar
• Rusnak , DW , Lackey , K , Affleck , K , Wood , ER , Alligood , KJ , Rhodes , N , Keith , BR , Murray , DM , Knight , WB , Mullin , RJ and Gilmer , TM . 2001 . The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo . Mol. Cancer Ther. , 1 : 85 – 94 .
   PubMed Web of Science ®Google Scholar
• Li , D , Ambrogio , L , Shimamura , T , Kubo , S , Takahashi , M , Chirieac , LR , Padera , RF , Shapiro , GI , Baum , A , Himmelsbach , F , Rettig , WJ , Meyerson , M , Solca , F , Greulich , H and Wong , KK . 2008 . BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models . Oncogene , 27 : 4702 – 4711 .
   PubMed Web of Science ®Google Scholar
• Allen , LF , Eiseman , IA , Fry , DW and Lenehan , PF . 2003 . CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer . Semin. Oncol. , 30 : 65 – 78 .
   PubMed Web of Science ®Google Scholar
• Bridges , AJ , Zhou , H , Cody , DR , Rewcastle , GW , McMichael , A , Showalter , HD , Fry , DW , Kraker , AJ and Denny , WA . 1996 . Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor . J. Med. Chem. , 39 : 267 – 276 .
   PubMed Web of Science ®Google Scholar
• Bos , M , Mendelsohn , J , Kim , YM , Albanell , J , Fry , DW and Baselga , J . 1997 . PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner . Clin. Cancer Res. , 3 : 2099 – 2106 .
   PubMed Web of Science ®Google Scholar
• Glide, version 5.5, Schrodinger, LLC, New York, NY, 2009
   Google Scholar